scispace - formally typeset
G

Giuliana Cassinelli

Researcher at University of Milan

Publications -  68
Citations -  7997

Giuliana Cassinelli is an academic researcher from University of Milan. The author has contributed to research in topics: Heparanase & Receptor tyrosine kinase. The author has an hindex of 32, co-authored 66 publications receiving 7311 citations. Previous affiliations of Giuliana Cassinelli include Sigma-Tau & University of Siena.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene

Maria Grazia Borrello, +15 more
- 11 Oct 2005 - 
TL;DR: It is shown that the RET/PTC1 oncogene induces the expression of a large set of genes involved in inflammation and tumor invasion, including those encoding chemokines, cytokines, and adhesion molecules.
Journal ArticleDOI

Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect

Silvia Stacchiotti, +11 more
- 01 Jul 2011 - 
TL;DR: Sunitinib activity in alveolar soft part sarcoma is confirmed, mediated by PDGFRB, VEGFR2, and RET, which are all expressed in tumor cells, and a direct antitumor effect was shown in a short-term cell culture.
Journal ArticleDOI

Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.

Giovanni Luca Beretta, +4 more
- 15 Dec 2017 - 
TL;DR: In-depth investigation on TKI chemosensitizing functions might provide a strong rationale for combining TKIs and conventional therapeutics in specific malignancies and open a new way towards anticancer therapy and clinical strategies aimed at counteracting drug resistance.
Journal ArticleDOI

Cellular Effects and Antitumor Activity of RET Inhibitor RPI-1 on MEN2A-Associated Medullary Thyroid Carcinoma

Giuditta Cuccuru, +10 more
- 07 Jul 2004 - 
TL;DR: The antitumor efficacy and oral bioavailability of RPI-1 support its therapeutic potential and Ret oncoproteins represent exploitable targets for therapeutic intervention in MEN2A-associated medullary thyroid carcinoma.